Memory and cognition
What human research has studied for memory, attention and cognitive decline, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where memory and cognition sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| Bacopa | B | Attention and reaction time in adults. A 2014 meta-analysis of nine RCTs (518 subjects; standardized extracts for 12 weeks or longer) found faster Trail B test and choice reaction times than placebo. sources |
| Bacopa | B | Memory in healthy adults. A 2026 network meta-analysis of 29 RCTs (2,107 healthy adults) reported better working memory with 600 mg/day or more than with placebo or ginkgo; it lacked direct head-to-head trials. sources |
| Citicoline (CDP-choline) | B | Memory and behavior in older people with chronic cerebral disorders. A 2005 Cochrane review of 14 double-blind placebo-controlled RCTs (most lasting 3 months or less; one 12 months) found some evidence of benefit on memory and behavior but none on attention. sources |
| Multivitamin/mineral supplements | B | Memory and cognition in older adults. A 2024 meta-analysis of three COSMOS substudies (573, 2,158 and 2,472 participants) found a daily multivitamin-mineral supplement improved global cognition (mean difference 0.07 SD units, 95% CI 0.03 to 0.11) and episodic memory versus placebo. sources |
| Algal oil (DHA and EPA) | C | Reading and behavior in underperforming schoolchildren. An RCT in healthy underperforming readers aged 7-9 (362 met criteria; 600 mg/day algal DHA) found no effect on reading overall, benefit in a pre-planned subgroup of the poorest readers, and fewer parent-rated behavior problems. sources |
| Arachidonic acid | C | Brain event-related potentials (P300) in healthy elderly men. A one-month double-blind crossover study in 25 men (240 mg/day ARA versus olive oil capsules) reported shorter P300 latency and higher P300 amplitude with ARA. sources |
| Asian ginseng | C | Cognitive function. A small amount of research suggests improvement in middle-aged but not young adults; memory benefit appeared to depend on adding ginkgo. sources |
| Bacopa | C | ADHD symptoms in children and adolescents. A 2022 systematic review of seven RCTs of herbal products found a 'fair indication' for bacopa among others, but inadequate proof overall to support herbal medicines for ADHD. sources |
| Benfotiamine | C | Cognitive decline in mild cognitive impairment or mild Alzheimer's disease. A 12-month phase IIa RCT (70 participants) found a 43% smaller ADAS-Cog increase with benfotiamine (p = 0.125, not significant) and 77% less worsening of clinical dementia rating (p = 0.034). sources |
| Carnosine (L-carnosine) | C | Cognitive function. In a 2026 review, five RCTs found no significant differences between L-carnosine and placebo on most cognitive measures; pooled benefits came from carnosine combined with anserine or antioxidants, with low strength of evidence. sources |
| Choline | C | Cognitive function in healthy adults. Observational studies linked higher choline status or intake to better cognition, but a 2015 systematic review of 13 studies found no clear cognitive improvement from choline in healthy adults. sources |
| Choline | C | Dementia (lecithin). A 2003 Cochrane review of 12 trials found no clear clinical benefit of lecithin for Alzheimer's disease or Parkinsonian dementia. sources |
| Citicoline (CDP-choline) | C | Cognitive status in mild cognitive impairment, Alzheimer's disease or post-stroke dementia. A 2023 meta-analysis of 6 studies found improved cognitive status with citicoline, but the overall quality of the studies was poor, with significant risk of bias favoring the intervention. sources |
| Copper | C | Alzheimer's disease and cognition. A 12-month trial (68 patients with mild Alzheimer's disease, 8 mg/day) found no cognitive difference from placebo; observational findings are mixed. sources |
| Folate (folic acid) | C | Cognitive function and dementia. Most trials show no benefit: 5,000 mcg for 18 months did not slow decline in 340 people with Alzheimer's; a Dutch trial (818 adults, 800 mcg, 3 years) improved some measures. sources |
| Ginkgo | C | Symptoms of dementia or cognitive impairment. Cochrane (2009): 36 trials, mostly small and under 3 months; results inconsistent, and authors found evidence of clinically significant benefit 'inconsistent and unreliable'. sources |
| Ginkgo | C | Cognitive performance in healthy people. NCCIH states it is uncertain whether ginkgo influences cognition in healthy people; much of the research is of low quality. sources |
| Gotu kola | C | Cognitive function. A 2017 meta-analysis of randomized trials (five of gotu kola alone) found no significant difference from placebo in any cognitive domain. sources |
| Guarana | C | Cognitive performance after a single dose. A 2023 meta-analysis of eight placebo-controlled studies (328 participants) found a small effect on faster response time but no effect on accuracy; whether this reflects caffeine or other constituents is unknown. sources |
| Guayusa | C | Attention and working memory after a single dose. A placebo-controlled crossover RCT of a single 650 mg extract dose reported better N-Back and Serial 7s performance and higher focus ratings than placebo over 2 hours, but fewer correct No-go responses. sources |
| Haritaki | C | Cognitive and negative symptoms in chronic schizophrenia. A 4-week double-blind RCT (six 500 mg capsules daily) reported improved cognitive-impairment scores, negative symptoms and excitement/activity versus placebo. sources |
| Holy basil | C | Cognitive performance in healthy adults. One 30-day placebo-controlled study (300 mg/day leaf extract) reported faster reaction times and fewer errors on Sternberg and Stroop tests. sources |
| Iodine | C | Cognitive function in mildly deficient children. One New Zealand trial (184 children aged 10–13, 150 mcg/day, 28 weeks) reported improved perceptual reasoning and overall cognitive score vs. placebo. sources |
| Kanna | C | Cognitive function in healthy adults. A 3-week crossover trial in 21 healthy adults (mean age 54.6, 25 mg daily) reported better cognitive set flexibility and executive function than placebo. sources |
| L-carnitine | C | Mild cognitive impairment and Alzheimer's disease (acetyl-L-carnitine). A 2003 Cochrane review of 11 trials in Alzheimer’s disease found more people improved on clinical global impression with acetyl-L-carnitine at 12 and 24 weeks but not at 52 weeks, no benefit on objective measures, and no evidence to recommend routine use. sources |
| Lion's mane | C | Mild cognitive impairment in older adults. RCT in 30 Japanese adults aged 50–80: tablets of dried lion's mane powder for 16 weeks raised cognitive scale scores versus placebo at weeks 8, 12 and 16; scores fell again 4 weeks after stopping. sources |
| Lion's mane | C | Mild Alzheimer's disease. 49-week pilot RCT (49 randomized, 41 completed): erinacine A-enriched mycelium capsules were linked to better MMSE and daily-activity scores than placebo, whose cognitive screening scores declined. sources |
| Lion's mane | C | Cognition, stress and mood in healthy young adults. Pilot RCT in 41 adults aged 18–45 (1.8 g): faster Stroop performance 60 minutes after one dose and a non-significant trend to lower stress after 28 days; other results were null. sources |
| Lutein and zeaxanthin | C | Cognitive function in adults. A 2021 meta-analysis of seven RCTs (five lutein/zeaxanthin supplement trials, two avocado trials) found no significant effect of lutein on complex attention, executive function or memory. sources |
| Maitake | C | Cognitive function in healthy older adults. RCT in 47 Japanese adults aged 60 or older: bread with 50 g of one maitake strain for 18 weeks improved MoCA-J scores versus placebo; a second strain showed no difference. sources |
| Mangosteen | C | Cognition in mild to moderate Alzheimer's disease. A 24-week RCT (108 participants) of a water-soluble pericarp extract found more participants in the low-dose group than on placebo reached a clinically important ADAS-Cog improvement, with a trend at the high dose. sources |
| MCT oil (medium-chain triglycerides) | C | Cognition in mild cognitive impairment or Alzheimer's disease. A 2023 meta-analysis (9 publications, 10 studies) found improved general cognition with oral MCT versus placebo, but not memory, language or attention; the authors say better-characterized studies are needed before a definitive conclusion. sources |
| Perilla | C | Leaf extract: cognitive impairment. In a 12-week RCT of 100 adults, 500 mg/day of a purple perilla leaf ethanol extract improved cognitive test scores versus placebo; blood amyloid and BDNF did not differ. The extract maker funded the study. sources |
| PQQ (pyrroloquinoline quinone) | C | Cognitive function in healthy middle-aged and older adults. A 12-week RCT (64 randomized, 58 completed; 21.5 mg/day PQQ disodium salt) reported better memory, attention and executive-function scores than placebo; no adverse events were observed. sources |
| PQQ (pyrroloquinoline quinone) | C | Attention in healthy elderly people. A 12-week RCT in 41 elderly subjects (20 mg/day) found a smaller change in Stroop interference ratio with PQQ than placebo; visual-spatial scores rose only in a low-scoring subgroup. sources |
| Rosemary | C | Memory speed in older adults (single doses). A crossover trial in 28 older adults found 750 mg of dried leaf improved speed of memory versus placebo, while 6,000 mg impaired it; other measures showed less consistent harmful effects. sources |
| Saffron | C | Mild cognitive impairment and Alzheimer's disease. A meta-analysis of four randomized trials found better cognitive scores than placebo, but the authors judged the evidence insufficient for any recommendation for clinical use. sources |
| Sage | C | Memory and thinking in healthy people. NCCIH: a few studies suggest common sage, Spanish sage or both may improve memory or other thinking scores in healthy people; the evidence is small. sources |
| Spearmint | C | Working memory in older adults with memory complaints. In a 90-day RCT of 90 adults with age-associated memory impairment, 900 mg/day extract improved quality of working memory (15%) and spatial working memory accuracy (9%) versus placebo; authors were funded by or employed by the manufacturer. sources |
| Spearmint | C | Attention in healthy young adults. In a 90-day RCT of 142 active adults, 900 mg/day extract improved sustained attention versus placebo; mood, sleep and quality of life did not differ. sources |
| Spermidine | C | Cognition in nursing-home residents with dementia. A 3-month double-blind preliminary study in 85 people aged 60–96 reported better test scores with a higher than a lower spermidine dose, mainly in mild dementia. sources |
| Taurine | C | Cognitive function. A 2025 meta-analysis of 7 RCTs (402 individuals) found taurine, alone or with exercise training, had no significant effect on cognitive scores; the authors found insufficient evidence of benefit. sources |
| Thiamin (vitamin B1) | C | Alzheimer's disease. A 2001 Cochrane review of three trials of 3 g/day oral thiamin, each with fewer than 20 patients, could not draw conclusions because the studies were small. sources |
| Vitamin B6 | C | Cognitive function. A systematic review of 14 RCTs found insufficient evidence of an effect; a Cochrane review found no evidence that 5–12 weeks of supplementation improved cognitive function or mood. sources |
| Vitamin E | C | Cognitive decline and Alzheimer's disease. In 341 people with moderate Alzheimer's, 2,000 IU/day for 2 years delayed functional decline but increased falls; trials in 769 people with mild cognitive impairment and in women found no benefit. sources |
| Ginkgo | X | Dementia risk in older adults. In the GEM trial, more than 3,000 people aged 75 or older took ginkgo or placebo for a median of 6 years; dementia and Alzheimer's rates did not differ. sources |
| Omega-3 fatty acids | X | Cognitive function in healthy older adults. ODS summarizes that trials found long-chain omega-3 supplementation does not affect cognitive function in healthy older adults; trials in people with Alzheimer's disease also found no benefit. sources |
| Perilla | X | Seed oil: cognition in mild to moderate dementia. In a 6-month add-on RCT (182 completers), perilla seed oil did not improve cognitive function versus placebo; total and LDL cholesterol were lower. sources |
| Phosphatidylserine | X | Memory in older adults with age-associated memory impairment. A 12-week randomized trial in 120 adults over 57 (300 or 600 mg/day soy-derived PS) found no effect on memory or other cognitive functions. sources |
| Resveratrol | X | Memory and cognition. A meta-analysis found no significant effect on memory or cognitive performance, and recent double-blind trials found no cognitive benefit in older adults. sources |
| Selenium | X | Cognitive decline and dementia. PREADVISE (about 7,540 men aged 60+, 200 mcg/day for 5.4 years) found no change in dementia incidence; a 2022 meta-analysis of 11 trials found no improvement in cognitive scores. sources |
| Spermidine | X | Memory in older adults with subjective cognitive decline. A 12-month randomized trial in 100 adults aged 60–90 (0.9 mg/day from wheat germ extract) found no effect on memory or biomarkers versus placebo; exploratory signals need confirmation. sources |
| Vitamin B12 | X | Cognitive function and dementia. A Cochrane review of 14 studies (27,882 participants) found little to no effect on global cognition for up to 5 years; a 2,919-adult RCT (500 mcg B12 plus folic acid, 2 years) found no difference. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.